Treatment of Non-BLEE Producing Klebsiella pneumoniae

Introduction to Treatment Strategies

The Taiwanese guidelines recommend explicitly that for infections by E. coli, K. pneumoniae, and Proteus mirabilis, antibiotic regimens should be de-escalated to first or second-generation cephalosporins according to susceptibility testing once it becomes available, with a strength of evidence supporting this approach 1, 2
This recommendation applies specifically to non-BLEE producing strains, where the antibiogram is reliable for guiding therapy, as supported by evidence from the Journal of Microbiology, Immunology and Infection 1, 2

For infections susceptible to narrow-spectrum cephalosporins, first-generation (cefazolin) or second-generation (cefuroxime) cephalosporins are appropriate when the antibiogram shows susceptibility, reducing the selective pressure for resistance development 1, 2
Cefalosporinas de tercera generación, such as cefotaxime 2g IV every 6-8 hours or ceftriaxone 2g IV daily, can be used for initial broader coverage, with evidence supporting their effectiveness 1, 2

For complicated urinary tract infections, treatment should last 7-10 days, as recommended by guidelines based on evidence 1, 2
For bacteremia, treatment duration is 7-14 days depending on the source and clinical response, with guidelines recommending this approach based on evidence 1, 2, 3
For pneumonia, treatment lasts 7-10 days for community-acquired pneumonia, with evidence supporting this duration 1, 2

Although K. pneumoniae may not produce BLEE, cefepime should be avoided when the MIC is in the susceptible dose-dependent category due to association with higher mortality, as cautioned by guidelines based on evidence 3
Local resistance patterns should guide initial empirical therapy, with guidelines emphasizing the importance of considering resistance patterns 1, 2